Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Stephen S Whitehead"'
Autor:
Alexandra M. Ortiz, Samuel J. Magaziner, Erik P. Karmele, Joseph C. Mudd, Jason M. Brenchley, Theodore C. Pierson, Stephen S. Whitehead, Shelly J. Robertson, Heather D. Hickman, Carol L. Vinton, Kimberly A. Dowd, Emerito Amaro-Carambot, Sonja M. Best, Carly E. Starke
Publikováno v:
mBio
mBio, Vol 10, Iss 6, p e02790-19 (2019)
mBio, Vol 10, Iss 6 (2019)
mBio, Vol 10, Iss 6, p e02790-19 (2019)
mBio, Vol 10, Iss 6 (2019)
Immunocompromised individuals often become symptomatic with infections which are normally fairly asymptomatic in healthy individuals. The particular mechanisms that underlie susceptibility to coinfections in human immunodeficiency virus (HIV)-infecte
Autor:
Konstantin A. Tsetsarkin, Stephen S. Whitehead, Cai-Yen Firestone, Tannya Castro-Jiménez, José Bustos-Arriaga, Gregory D. Gromowski, Alexander G. Pletnev, Leticia Cedillo-Barrón
Publikováno v:
Vaccine. 36:3460-3467
The NIH has developed live attenuated dengue virus (DENV) vaccine candidates by deletion of 30 nucleotides (Δ30) from the untranslated region of the viral genome. Although this attenuation strategy has proven to be effective in generating safe and i
Autor:
Stephen S. Whitehead, Ethan Weinberg, Amadou A. Sall, Christopher T. Hanson, Eric B. Fokam, Scott C. Weaver, Nikos Vasilakis, Kathryn A. Hanley
Publikováno v:
Virology. 377(2):296-307
The four serotypes of endemic dengue viruses (DENV) circulate between humans and peridomestic Aedes mosquitoes. At present endemic DENV infect 100 million people per year, and a third of the global population is at risk. In contrast, sylvatic DENV st
Autor:
Brian R. Murphy, Christopher T. Hanson, Stephen S. Whitehead, James M. Speicher, Joseph E. Blaney, Alexander G. Pletnev, Neeraj S. Sathe
Publikováno v:
Vaccine. 26:4150-4159
To develop a live attenuated virus vaccine against St. Louis encephalitis (SLE) virus, two antigenic chimeric viruses were generated by replacing the membrane precursor and envelope protein genes of dengue virus type 4 (DEN4) with those from SLE with
Autor:
Moises Lopez-Gonzalez, Julio García-Cordero, René A. Méndez-Cruz, Stephen S. Whitehead, Francisco J. Juárez-Delgado, Leticia Cedillo-Barrón, Rick M. Fairhurst, José Bustos-Arriaga, Gregory D. Gromowski, Neida K. Mita-Mendoza
Publikováno v:
Immunologic research. 64(2)
When dengue virus (DENV)-infected mosquitoes use their proboscis to probe into human skin during blood feeding, both saliva and virus are released. During this process, cells from the epidermis and dermis layers of the skin, along with small blood ve
Autor:
Heather Kenney, José Bustos-Arriaga, Stephen S. Whitehead, Guangping Liu, Alexander G. Pletnev, Christopher T. Hanson, Konstantin A. Tsetsarkin
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 11, Iss 4, p e1004852 (2015)
PLoS Pathogens, Vol 11, Iss 4, p e1004852 (2015)
Mosquito-borne flaviviruses are among the most significant arboviral pathogens worldwide. Vaccinations and mosquito population control programs remain the most reliable means for flavivirus disease prevention, and live attenuated viruses remain one o
Publikováno v:
Journal of Virology. 79:5516-5528
The mosquito-borne dengue (DEN) viruses, members of the Flaviviridae family, contain a single-stranded positive-sense RNA genome (36). A single polypeptide is cotranslationally processed by viral and cellular proteases generating three structural pro
Autor:
Brian R. Murphy, Cai Yen Firestone, Stephen S. Whitehead, Daniel H. Johnson, Joseph E. Blaney, Christopher T. Hanson, Gracielle G Manipon
Publikováno v:
Vaccine. 21:4317-4327
Mutations which increase the replication of dengue viruses in cell culture would greatly facilitate the manufacture of both a live attenuated or inactivated dengue virus vaccine. We have identified eight missense mutations in dengue virus type 4 (DEN
Autor:
Kathryn A. Hanley, Stephen S. Whitehead, Brian R. Murphy, Lara E Gilmore, William R. Elkins, Joseph E. Blaney
Publikováno v:
Vaccine. 21:4307-4316
Antigenic chimeric viruses in which the structural genes of dengue virus type 4 (DEN4) have been replaced with those derived from dengue virus type 2 (DEN2) have been created and evaluated as a first step in generating a live attenuated tetravalent d
Autor:
Kathryn A. Hanley, Ruth A. Karron, Anna P. Durbin, Jill M. Troyer, Daniel Strickman, Brian R. Murphy, Stephen S. Whitehead
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 65:414-419
2Adelta30 is a live dengue-4 virus vaccine candidate with a 30-nucleotide deletion in its 3'-untranslated region. To assess the transmissibility of 2Adelta30 by mosquitoes, we compared its in vivo replication in mosquitoes with that of its wild type